What does therapeutic development — cost of revenue mean?

This reflects the direct costs incurred to generate revenue within the therapeutic development segment, including materials, labor, and overhead directly attributable to these activities. Monitoring this metric helps assess the direct profitability and cost efficiency of the segment's commercial operations.

Fulgent Genetics, Inc. FLGT Therapeutic Development — Cost Of Revenue

Other segment segments

Laboratory Services

$48.18M+11.2%

Similar metrics at other companies

MLABBiopharmaceutical Development — Cost Of Revenue

$3.65M-32.0%

MMSITherapeutic — Revenue

$126.4M+9.9%

LASRDevelopment — Total Cost of Revenue

$20.86M+47.5%

MLABBiopharmaceutical Development — Cost Of Revenue Other

$3.2M-35.4%

CBLLProduct — Cost Of Revenue

$3.07M+30.0%

VCYTTesting revenue — Cost of Revenue

$33.31M+17.9%

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — cost of revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s therapeutic development — cost of revenue?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — cost of revenue of $8K in Q1 2026.
What does therapeutic development — cost of revenue mean?: This reflects the direct costs incurred to generate revenue within the therapeutic development segment, including materials, labor, and overhead directly attributable to these activities. Monitoring this metric helps assess the direct profitability and cost efficiency of the segment's commercial operations.